Clearwater Capital Advisors LLC Buys New Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Clearwater Capital Advisors LLC purchased a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 3,337 shares of the company’s stock, valued at approximately $209,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CRSP. Blue Trust Inc. bought a new stake in shares of CRISPR Therapeutics in the 4th quarter worth approximately $32,000. Bourgeon Capital Management LLC lifted its position in shares of CRISPR Therapeutics by 1,000.0% in the 4th quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock worth $34,000 after purchasing an additional 500 shares during the period. TFC Financial Management Inc. boosted its stake in shares of CRISPR Therapeutics by 3,400.0% during the 4th quarter. TFC Financial Management Inc. now owns 700 shares of the company’s stock valued at $44,000 after purchasing an additional 680 shares in the last quarter. Tradewinds Capital Management LLC raised its stake in CRISPR Therapeutics by 545.5% in the third quarter. Tradewinds Capital Management LLC now owns 710 shares of the company’s stock worth $32,000 after buying an additional 600 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new stake in CRISPR Therapeutics in the third quarter worth about $34,000. Institutional investors own 69.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on CRSP shares. Royal Bank of Canada raised their target price on CRISPR Therapeutics from $57.00 to $66.00 and gave the company a “sector perform” rating in a research note on Thursday, February 22nd. TheStreet upgraded shares of CRISPR Therapeutics from a “d+” rating to a “c” rating in a research note on Friday, February 23rd. Mizuho boosted their price objective on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th. Wolfe Research started coverage on shares of CRISPR Therapeutics in a research note on Thursday, February 15th. They set a “peer perform” rating for the company. Finally, Morgan Stanley boosted their price target on CRISPR Therapeutics from $46.00 to $48.00 and gave the stock an “underweight” rating in a research report on Monday, February 26th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $76.29.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 20,000 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $80.36, for a total transaction of $1,607,200.00. Following the completion of the sale, the chief executive officer now owns 187,377 shares of the company’s stock, valued at $15,057,615.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $80.36, for a total value of $1,607,200.00. Following the completion of the transaction, the chief executive officer now directly owns 187,377 shares in the company, valued at $15,057,615.72. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, General Counsel James R. Kasinger sold 1,913 shares of CRISPR Therapeutics stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $152,408.71. Following the transaction, the general counsel now owns 57,371 shares in the company, valued at approximately $4,570,747.57. The disclosure for this sale can be found here. Insiders sold 83,992 shares of company stock worth $6,132,335 in the last three months. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Trading Down 4.0 %

CRSP stock traded down $2.24 during trading on Wednesday, reaching $53.29. The stock had a trading volume of 1,539,253 shares, compared to its average volume of 1,760,795. The firm has a market cap of $4.52 billion, a PE ratio of -27.19 and a beta of 1.80. The stock’s 50 day moving average is $65.81 and its two-hundred day moving average is $64.64. CRISPR Therapeutics AG has a 52 week low of $37.55 and a 52 week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.95. The business had revenue of $201.20 million during the quarter, compared to analysts’ expectations of $148.72 million. During the same period in the previous year, the business posted ($1.41) EPS. The business’s quarterly revenue was up 3253.3% compared to the same quarter last year. On average, research analysts anticipate that CRISPR Therapeutics AG will post -6.24 EPS for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.